Lipoprotein complexes and manufacturing and uses thereof
The present disclosure relates to lipoprotein complexes and lipoprotein populations and their use in the treatment and/or prevention of dyslipidemic diseases, disorders, and/or conditions. The disclosure further relates to recombinant expression of apolipoproteins, purification of apolipoproteins, and production of lipoprotein complexes using thermal cycling-based methods.
1. A method for preparing lipoprotein complexes, comprising:
(a) cooling a starting suspension comprising a lipid component and a protein component from a temperature in a first temperature range to a temperature in a second temperature range, wherein said first temperature range includes temperatures no less than 10 degrees below and no more than 15 degrees above the transition temperature of said protein component, and wherein
(i) the lipid component consists essentially of particles of lipids formed by homogenization; and
the protein component consists essentially of lipid-binding peptides and/or lipid-binding proteins that have not been subject to homogenization and, optionally, a lipid in an amount that is 10% or less by weight of the total amount of lipid in the starting suspension;
(ii)
(b) heating the cooled suspension of (a) from a temperature in said second temperature range to a temperature in said first temperature range;
(c) cooling said heated suspension of (b) from a temperature in said first temperature range to a temperature in said second temperature range; and
(d) repeating steps (b) and (c) until at least 80% of the protein component is incorporated into lipoprotein complexes, thereby forming lipoprotein complexes.
2. A method for preparing lipoprotein complexes, comprising:
(a) cooling a starting suspension comprising a lipid component and a protein component from a temperature in a first temperature range to a temperature in a second temperature range, wherein
(i) the lipid component comprises neutral lipids and consists essentially of particles of lipids formed by homogenization; and
(ii) the protein component consists essentially of lipid-binding peptides and/or lipid-binding proteins that have not been subject to homogenization pre-complexed with negatively charged lipids, wherein the negatively charged lipids are in an amount that is 10% or less by weight of the total amount of lipid in the starting suspension;
(b) heating the cooled suspension of (a) from a temperature in said second temperature range to a temperature in said first temperature range;
(c) cooling said heated suspension of (b) from a temperature in said first temperature range to a temperature in said second temperature range; and
(d) repeating steps (b) and (c) until at least 80% of the protein component is incorporated into lipoprotein complexes, thereby forming lipoprotein complexes.
3. The method of claim 1 or claim 2 , wherein step (d) comprises repeating steps (b) and (c) at least three times.
4. The method of claim 1 or claim 2 , wherein step (d) comprises repeating steps (b) and (c) until at least 85% of the protein component is incorporated into lipoprotein complexes.
5. The method of claim 1 or claim 2 , wherein step (d) comprises repeating steps (b) and (c) until lipoprotein complexes of 4 nm to 15 nm in diameter, as measured by gel filtration chromatography, are obtained.
6. The method of claim 2 , wherein said first temperature range includes temperatures no less than 10 degrees below and no more than 15 degrees above the transition temperature of said protein component.
7. The method of claim 1 or claim 2 , wherein said second temperature range includes temperatures no less than 10 degrees below and no more than 5 degrees above the transition temperature of said lipid component.
8. The method of claim 1 , wherein said lipid component comprises neutral lipids.
9. The method of claim 8 , wherein the starting suspension comprises negatively charged lipids.
10. The method of claim 1 , wherein said protein component consists essentially of lipid-binding proteins that have not been subject to homogenization and, optionally, a lipid in an amount that is 10% or less by weight of the total amount of lipid in the starting suspension.
11. The method of claim 1 or claim 2 , wherein the lipid:protein molar ratio in said starting suspension is from about 2:1 to about 200:1.
12. The method of claim 1 or claim 2 , further comprising the step of forming said starting suspension by a process comprising combining the lipid component and the protein component.
13. The method of claim 12 , wherein the lipid component and the protein component are each preheated at a temperature in said first temperature range.
14. The method of claim 12 , which further comprises, prior to the step of forming the starting suspension, a step of forming the lipid particles using high pressure homogenization.
15. The method of claim 1 or claim 2 , in which the lipid component consists essentially of lipid particles, said lipid particles being: at least 45 nm in diameter, as measured by gel permeation chromatography; and up to 500 nm in diameter as measured by gel permeation chromatography.
16. The method of claim 1 or claim 2 , wherein the starting suspension contains negatively charged lipid, neutral lipid and lipid-binding peptides in a molar ratio ranging from 2-6 (negatively charged lipid): 90-120 (neutral lipid): 1 (lipid-binding peptide, lipid binding protein or mixtures thereof).
17. The method of claim 1 or claim 2 , which further comprises the step of lyophilizing the resulting lipoprotein complexes.
18. The method of claim 1 or claim 2 , wherein the lipid component consists essentially of particles of lipids formed by high pressure homogenization.
19. The method of claim 1 or claim 2 , wherein step (d) comprises repeating steps (b) and (c) until at least 90% of the protein component is incorporated into lipoprotein complexes.
20. The method of claim 1 or claim 2 , wherein step (d) comprises repeating steps (b) and (c) until at least 95% of the protein component is incorporated into lipoprotein complexes.
21. The method of claim 2 or claim 8 , wherein the neutral lipids consist essentially of sphingomyelin.
22. The method of claim 2 or claim 9 , wherein the negatively charged lipids consist essentially of 1,2-dipalmitoyl-sn-glycero-3-[phospho-rac-(1-glycerol)] (“DPPG”).
23. The method of claim 22 , wherein the neutral lipids consist essentially of sphingomyelin.
24. The method of claim 1 or claim 2 , wherein the protein component consists essentially of Apolipoprotein A-I (ApoA-I).
25. The method of claim 23 , wherein the protein component consists essentially of Apolipoprotein A-I (ApoA-I).
26. The method of claim 1 or claim 2 , wherein the starting suspension does not contain detergent.
27. The method of claim 9 , wherein the negatively charged lipids are pre-complexed with the lipid-binding peptides and/or lipid-binding proteins.
28. The method of claim 2 or claim 27 , further comprising the step of forming the protein component by a process comprising combining the lipid-binding peptides and/or lipid-binding proteins and the negatively charged lipids.
29. The method of claim 2 , wherein said protein component consists essentially of lipid-binding proteins that have not been subject to homogenization pre-complexed with negatively charged lipids, wherein the negatively charged lipids are in an amount that is 10% or less by weight of the total amount of lipid in the starting suspension.
30. The method of claim 18 , wherein the high pressure homogenization comprises microfluidization.
31. A method for making a pharmaceutical composition, comprising:
(a) preparing a population of lipoprotein complexes according to the method of claim 1 or claim 2 ; and
(b) combining said population of lipoprotein complexes with one or more pharmaceutically acceptable excipients.
32. A method for making a pharmaceutical composition, comprising:
(a) preparing a population of lipoprotein complexes according to the method of claim 25 ; and
(b) combining said population of lipoprotein complexes with one or more pharmaceutically acceptable excipients.